News for Revolution Medicines, Inc. (RVMD)

Summary Revolution Medicines Inc (RVMD), a clinical-stage oncology company, announced on July 24, 2025, the publication of a peer-reviewed research paper in the

Revolution Medicines (RVMD) has published a peer-reviewed paper detailing the discovery of the RAS(ON) G12D-selective inhibitor, zoldonrasib. Zoldonrasi

FDA grants Breakthrough Therapy Designation to Revolution Medicines' elironrasib for KRAS G12C-mutated non-small cell lung cancer (NSCLC). Phase 1 trial sho

Summary Revolution Medicines Inc (RVMD), a late-stage clinical oncology company, announced on July 23, 2025, that the U.S. Food and Drug Administration (FDA) ha

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best oversold NASDAQ stocks to buy now. On July 15, Goldman Sachs analyst Andrea Newkirk initiated a new Buy rating on Revolution Medicines, Inc. (NASDAQ:RVMD) with a $65 price target. The analyst based the rating on the company’s promising clinical developments and strategic focus, stating that Revolution Medicines, […]

On July 14, Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.

Revolution Medicines (RVMD) received attention from financial giant Goldman Sachs as they initiated coverage on the company with a 'Buy' rating. The announcemen

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Goldman Sachs has started coverage on Revolution Medicines (RVMD), giving it a Buy rating with a target price of $65. The investment bank identifies Revolution

Summary Revolution Medicines Inc (RVMD), a clinical-stage oncology company, has announced a strategic collaboration with Iambic Therapeutics to leverage AI tech

Custom-built model will be trained using Revolution Medicines' proprietary data to discover novel drug candidatesIambic to receive up to $25 million through a c

Revolution Medicines, Inc. (NASDAQ:RVMD) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Oppenheimer analysts maintained their $75 price target for Revolution Medicines, Inc. (NASDAQ:RVMD) and reaffirmed their Outperform rating on June 3. Updates from competing KRAS initiatives that were given at this year’s ASCO meeting coincide with […]

Tango Therapeutics (TNGX) initiates Phase 1/2 trial with TNG462 for cancer treatment. The trial combines TNG462 with Revolution Medicines' daraxonrasib or z

Revolution Medicines, identified by the ticker RVMD, has received a significant boost as the U.S. Food and Drug Administration has awarded Breakthrough Therapy

Revolution Medicines' pan-RAS inhibitors show promise for tough cancers.

On June 9, 2025, Logos Global Management LP (Trades, Portfolio) executed a significant transaction by acquiring 4,800,000 shares of Arvinas Inc at a price of $7

On June 10, 2025, Casdin Capital, LLC (Trades, Portfolio) executed a notable transaction involving BioLife Solutions Inc. The firm reduced its holdings in the c

On May 14, 2025, HC Wainwright & Co., a reputable investment research firm, maintained its "Buy" rating for Revolution Medicines (RVMD). This decision was made

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ( RVMD), a late-stage clinical oncology company developing targeted therapie